Description
Humana Press Acute Myelogenous Leukemia 1st Editon 2010 Softbound by Judith E. Karp
Acute Myelogenous Leukemia is a timely compilation of new concepts in the molecular pathogenesis and molecular therapy of acute myelogenous leukemia (AML). The focus is on selected critical molecular determinants of AML pathogenesis and pathophysiology and the exploitation of these factors by diverse therapeutic agents and modalities. Bringing together new concepts and findings in the basic and clinical science of AML, the book emphasizes the molecular basis for new therapies that stand to have the greatest potential impact on the clinical face of these diseases. The text provides insights into selected novel strategies currently and prospectively being developed, including interruption of specific signal transduction pathways, modulation of gene expression, attempts to reinstate differentiation, and immunomodulation. There is an emphasis throughout on the bidirectional flow of knowledge between the clinical and laboratory arenas, and both basic and clinical scientists will benefit from this translational text. Overview of AML.- Approaching the Treatment of AML from a Biological Perspective.- Molecular Foundations of AML Pathogenesis and Physiology.- Aberrant Transcription Factors in AML.- Myelodysplasia-Related AML.- Therapy-related AML.- The DNA Damage Response, DNA Repair, and AML.- Altered Apoptosis in AML.- Drug Resistance Transporters in AML.- Translating Biology into Clinical Application.- Impact of Cytogenetics on Clinical Outcome in AML.- APL: A Classic Tale of Bench to Bedside.- Molecular Therapeutics of AML: Selected Targeted Approaches.- Emerging Therapeutics for AML.- FLT3: A Prototype Receptor Tyrosine Kinase Target in AML.- Farnesyl Transferase Inhibitors in the Therapy of AML.- Modulating Gene Expression as a Therapeutic Approach in the Treatment of AML.- Differentiation Therapy in AML.- Stem Cell Transplantation for AML.- Tumor Vaccines in Leukemia.- Special Challenges.- Treatment, Outcomes, and Challenges of Newly Diagnosed AML in Children and Adolescents.- AML in Older Adults.- Dameshek Smiles: Molecular Clues to the Chronic Myeloproliferative Disorders Unmasked.- New Designs for Clinical Trials.